HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sohei Yamamoto Selected Research

Clear Cell Adenocarcinoma

6/2012ACTN4 gene amplification and actinin-4 protein overexpression drive tumour development and histological progression in a high-grade subset of ovarian clear-cell adenocarcinomas.
5/2012Aberrant expression of the mammalian target of rapamycin, hypoxia-inducible factor-1α, and glucose transporter 1 in the development of ovarian clear-cell adenocarcinoma.
1/2012PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma.
8/2011Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient.
11/2009Aberrant expression of p27(Kip1)-interacting cell-cycle regulatory proteins in ovarian clear cell carcinomas and their precursors with special consideration of two distinct multistage clear cell carcinogenetic pathways.
4/2009Actinin-4 gene amplification in ovarian cancer: a candidate oncogene associated with poor patient prognosis and tumor chemoresistance.
2/2008Expression of platelet-derived growth factors and their receptors in ovarian clear-cell carcinoma and its putative precursors.
7/2007Immunohistochemical detection of hepatocyte nuclear factor 1beta in ovarian and endometrial clear-cell adenocarcinomas and nonneoplastic endometrium.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Sohei Yamamoto Research Topics

Disease

20Neoplasms (Cancer)
01/2021 - 08/2007
12Carcinoma (Carcinomatosis)
01/2021 - 07/2007
8Clear Cell Adenocarcinoma
06/2012 - 07/2007
6Endometriosis
04/2012 - 07/2007
5Ovarian Neoplasms (Ovarian Cancer)
08/2021 - 12/2007
4Neoplasm Metastasis (Metastasis)
08/2012 - 08/2007
3Adenocarcinoma
01/2021 - 07/2007
3Adenoma (Adenomas)
01/2018 - 08/2015
3Breast Neoplasms (Breast Cancer)
05/2012 - 10/2010
2Colorectal Neoplasms (Colorectal Cancer)
01/2018 - 12/2007
2Polyps
01/2018 - 09/2017
2Carcinogenesis
07/2017 - 06/2012
2Stomach Neoplasms (Stomach Cancer)
08/2015 - 08/2012
2Seminoma
11/2012 - 09/2010
2Embryonal Carcinoma
11/2012 - 09/2010
2Germ Cell and Embryonal Neoplasms (Germ Cell Tumor)
11/2012 - 09/2010
2Cystadenofibroma
04/2012 - 02/2008
1Cysts
08/2021
1Coinfection
06/2019
1Infectious Mononucleosis (Glandular Fever)
06/2019
1Hepatocellular Carcinoma (Hepatoma)
05/2019
1Sertoli-Leydig Cell Tumor
05/2019
1Intestinal Neoplasms (Intestinal Cancer)
01/2018
1Squamous Cell Carcinoma (Epidermoid Carcinoma)
07/2017
1Hyperkalemia
08/2012
1Tumor Lysis Syndrome
08/2012
1Hyperuricemia
08/2012
1Hypoxia (Hypoxemia)
05/2012
1Triple Negative Breast Neoplasms
04/2012
1Lymphatic Metastasis
02/2011
1Choriocarcinoma
09/2010
1Endodermal Sinus Tumor (Endodermal Sinus Tumors)
09/2010
1Teratoma (Teratoid Tumor)
09/2010
1Lung Neoplasms (Lung Cancer)
12/2007

Drug/Important Bio-Agent (IBA)

13Proteins (Proteins, Gene)FDA Link
01/2018 - 04/2009
3Cyclin EIBA
11/2012 - 11/2009
3Cyclin AIBA
11/2012 - 11/2009
3DNA (Deoxyribonucleic Acid)IBA
05/2012 - 10/2011
3Biological ProductsIBA
02/2008 - 07/2007
2polysulfideIBA
08/2021 - 01/2021
2PlatinumIBA
01/2021 - 09/2011
2ParaffinIBA
05/2019 - 10/2010
2Histidine (L-Histidine)FDA Link
09/2017 - 07/2017
2Cytidine DeaminaseIBA
07/2017 - 08/2015
2Cadherins (E-Cadherin)IBA
07/2017 - 07/2017
2ActininIBA
06/2012 - 12/2007
2Indicators and Reagents (Reagents)IBA
10/2011 - 12/2007
2ErbB Receptors (EGF Receptor)IBA
10/2010 - 09/2010
2VimentinIBA
07/2010 - 08/2007
2Mucin-1 (CA 15-3 Antigen)IBA
07/2010 - 08/2007
1Cisplatin (Platino)FDA LinkGeneric
01/2021
1sulfur-32IBA
01/2021
1monobromobimaneIBA
01/2021
1Ambroxol (Mucosolvan)IBA
01/2021
1CystathionineIBA
01/2021
1Expectorants (Mucolytics)IBA
01/2021
1LyasesIBA
01/2021
1SulfurIBA
01/2021
1Antiviral Agents (Antivirals)IBA
06/2019
1Immunoglobulin M (IgM)IBA
06/2019
1ElementsIBA
05/2019
1alpha-Fetoproteins (alpha-Fetoprotein)IBA
05/2019
1erucylphosphocholineIBA
09/2017
1Calcibiotic Root Canal SealerIBA
09/2017
1Cyclooxygenase 2 (Cyclooxygenase-2)IBA
09/2017
1theasinensin AIBA
09/2017
1MutL Protein Homolog 1IBA
09/2017
1MutS ProteinsIBA
09/2017
1CarcinogensIBA
07/2017
1CreatinineIBA
08/2012
1S-1 plus cisplatinIBA
08/2012
1TOR Serine-Threonine KinasesIBA
05/2012
1Facilitative Glucose Transport Proteins (Glucose Transporter)IBA
05/2012
1Hormones (Hormone)IBA
04/2012
1Therapeutic UsesIBA
04/2012
1Phosphotransferases (Kinase)IBA
10/2011
1Biomarkers (Surrogate Marker)IBA
08/2011
1Trastuzumab (Herceptin)FDA Link
10/2010
1Formaldehyde (Formol)FDA Link
10/2010
1Keratins (Keratin)IBA
07/2010
1Calbindin 2IBA
07/2010
1Cyclin-Dependent Kinases (cdk Proteins)IBA
05/2010
1Cell Cycle ProteinsIBA
11/2009
1Proto-Oncogene Proteins c-sis (Platelet Derived Growth Factor B)IBA
02/2008
1Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA
02/2008
1Platelet-Derived Growth FactorIBA
02/2008
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
02/2008
1LigandsIBA
02/2008
1platelet-derived growth factor AIBA
02/2008
1Protein Isoforms (Isoforms)IBA
12/2007
1DesminIBA
08/2007
1MyoglobinIBA
08/2007
1Phosphopyruvate Hydratase (Enolase)IBA
08/2007
1Hepatocyte Nuclear Factor 1-betaIBA
07/2007

Therapy/Procedure

4Drug Therapy (Chemotherapy)
01/2021 - 04/2009
3Therapeutics
04/2012 - 08/2007
1Pancreaticoduodenectomy
08/2021
1Cytoreduction Surgical Procedures
05/2019
1Neoadjuvant Therapy
04/2012
1Neck Dissection (Radical Neck Dissection)
02/2011